Table 4 Relations between NLRP3 (rs10754558) genotypes with different clinical parameters in psoriasis patients (n = 75)
Variables | NLRP3 (rs10754558) genotype | Test of sig | P value | ||
|---|---|---|---|---|---|
GG (n = 18) | CC (n = 13) | GC (n = 44) | |||
⁰Gender, n (%) | |||||
Male Female | 9(50%) 9(50%) | 5(38.5%) 8(61.5%) | 24(54.5%) 20(45.5%) | 1.043 | 0.594 |
⁰Family History, n (%) | |||||
Yes No | 9(50%) 9(50%) | 1(7.7%) 12(92.3%) | 8(18.2%) 36(81.8%) | 2.316 | 0.330 |
⁑ Duration of disease(yrs.), median (IQR) | 4(5.5) | 3(4.5) | 4(6.8) | 0.293 | 0.864 |
*Psoriatic Arthritis, n (%) | |||||
Yes No | 3(16.7%) 15(83.3%) | 1(7.7%) 12(92.3%) | 8(18.2%) 36(81.8%) | 0.679 | 0.826 |
*Treatment line, n (%) | |||||
Methotrexate Adalimumab | 16(88.9%) 2(11.1%) | 13(100%) 0(0%) | 40(90.9%) 4(9.1%) | 1.164 | 0.711 |
⁑ Treatment duration (mons), median (IQR) | 6.5(5) | 8(8) | 12(25) | 13.926 | 0.001 |
⁑ Baseline PASI, median (IQR) | 36.5(30) | 20(8) | 30(24) | 7.84 | 0.02 |
⁑ Therapeutic PASI, median (IQR) | 30(32) | 12(5) | 32(25) | 12.325 | 0.002 |
⁰Severity, n (%) | |||||
Mild Moderate Severe | 0(0%) 8(44.4%) 10(55.6%) | 0(0%) 12(92.3%) 1(7.7%) | 4(9.1%) 8(18.2%) 32(72.7%) | 25.32 | < 0.001* |